Portal de Periódicos da CAPES

Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05–2013/14, Toronto, Canada

2017; Elsevier BV; Volume: 140; Linguagem: Inglês

10.1016/j.antiviral.2017.01.025

1872-9096

Brenda L. Coleman, Kazi Hassan, Karen Green, Jonathan B. Gubbay, Kevin Katz, Tony Mazzulli, Shelly McNeil, Matthew Muller, Jeff Powis, David Richardson, Andrew E. Simor, Allison McGeer,

Viral Infections and Immunology Research

Data on factors associated with the use of antiviral medication to treat influenza in both children and adults are limited. To describe trends in antiviral use, analyze factors associated with antiviral treatment of hospitalized patients with influenza, and to compare use based on guidelines. A retrospective observational cohort of hospitalized patients with laboratory confirmed influenza in southern Ontario hospitals for the 2004/05–2013/14 seasons. Of the 7967 patients, 18% of the 1779 children (<15 years) and 66% of the 6188 adults received antiviral therapy. The percentage treated increased from 29% pre-pandemic to 74% during the pandemic, decreased to 55% in 2011/12 and then increased to 65% in 2013/14. Factors significantly associated with antiviral prescription across all age groups during the non-pandemic seasons include influenza type, disease severity, interval between symptom onset and test sample submission, and clinician suspicion of influenza. Rate of treatment of patients meeting guideline criteria was low for children and moderate for adults. Since the pandemic, there has been a sustained increase in the use of antiviral medication for all age groups of hospitalized patients with influenza, but much higher for adults than children. The odds of treatment are higher for patients with more severe disease as well as for those tested within 48 h of symptom onset, both of which are part of the guidelines for treatment with anti-influenza medications.